The estimated Net Worth of Sagar Lonial is at least $3.75 Milion dollars as of 17 June 2024. Sagar Lonial owns over 25,933 units of TG Therapeutics Inc stock worth over $2,426,849 and over the last 4 years he sold TGTX stock worth over $1,327,060. In addition, he makes $0 as Independent Director at TG Therapeutics Inc.
Sign up
Sagar Lonial TGTX stock SEC Form 4 insiders trading
Sagar has made over 3 trades of the TG Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 25,933 units of TGTX stock worth $432,822 on 17 June 2024.
The largest trade he's ever made was selling 34,854 units of TG Therapeutics Inc stock on 23 June 2023 worth over $814,538. On average, Sagar trades about 9,398 units every 51 days since 2020. As of 17 June 2024 he still owns at least 105,195 units of TG Therapeutics Inc stock.
You can see the complete history of Sagar Lonial stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sagar Lonial biography
Dr. Sagar Lonial M.D. serves as Independent Director of the Company. Dr. Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research. As a medical oncologist at the Winship Cancer Institute, Dr. Lonial treats patients with multiple myeloma and is a lead member of the bone marrow transplantation team and clinical trials team. He is board certified in hematology and medical oncology. Dr. Lonial is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the board of directors for the International Myeloma Society, and on the scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. Based on Dr. Lonial’s medical background and significant experience in oncology drug development, the Board of Directors believes that Dr. Lonial has the appropriate set of skills to serve as a member of the Board.
How old is Sagar Lonial?
Sagar Lonial is 53, he's been the Independent Director of TG Therapeutics Inc since 2020. There are 6 older and 2 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
What's Sagar Lonial's mailing address?
Sagar's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, , MORRISVILLE, NC, 27560.
Insiders trading at TG Therapeutics Inc
Over the last 13 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss a Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
What does TG Therapeutics Inc do?
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
What does TG Therapeutics Inc's logo look like?
Complete history of Sagar Lonial stock trades at TG Therapeutics Inc
TG Therapeutics Inc executives and stock owners
TG Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Weiss,
Executive Chairman of the Board, President, Chief Executive Officer -
Michael S. Weiss Esq.,
Chairman, CEO & Pres -
Sean Power,
Chief Financial Officer, Treasurer, Corporate Secretary -
Sean A. Power CPA, CPA,
CFO, Corp. Sec. & Treasurer -
Laurence Charney,
Independent Director -
Kenneth Hoberman,
Independent Director -
William Kennedy,
Independent Director -
Daniel Hume,
Independent Director -
Yann Echelard,
Independent Director -
Jenna Bosco,
Senior Vice President - Corporate Communications -
Sagar Lonial,
Independent Director -
Kelly Ross,
Chief Technology Officer -
Adam Waldman,
Chief Commercial Officer -
Dr. Owen A. O'Connor,
Chief Scientific Officer -
Biotechnologies S.A.S.U. Lfb,
10% owner -
Mark Schoenebaum,
Director -
Neil Herskowitz,
Director -
Capital Management, L.P.Kol...,